Alba Therapeutics reports excellent results from Phase IIb trial of larazotide acetate for CeD treatment Today the positive results of their Phase IIb trial evaluating its investigational product Alba Therapeutics Corporation announced, larazotide acetate, a first-in-course tight junction regulator, designed for the treatment of patients with celiac disease . The study met its major endpoint and, based on these results, Alba provides initiated planning for Phase III clinical trials for the definitive assessment of the oral peptide's efficacy and safety. The final data shall be submitted for publication soon. The double-blind, placebo-controlled research evaluated the efficacy and safety of larazotide acetate in the treating 342 patients with CeD who experienced persistent symptoms despite getting on a gluten-free diet plan.These children were 5.1 times as more likely to become obese during the subsequent 9 years as were children with the same high birth weight whose growth trajectories led to a normal weight at the age of 5 years. Quantifying Pounds Trajectories Children at the 50th %ile of body-mass index at the age of 5 years had a 6 percent possibility of being obese in age 14 years , According to z Rating and Percentile of Body-Mass Index at Previous Ages.). This probability increased to 25 percent among 5-year-olds at the 85th %ile and to 47 percent among those at the 95th %ile. Among children who had been at the 99th %ile in kindergarten, 72 percent could be prepared to still end up being obese as they completed eighth grade. Discussion The incidence of obesity between the ages of 5 and 14 years was 4 times as high among children who was simply overweight at age 5 years as among children who had a normal weight at that age.